Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications
Alerting Network Dysfunction in Early Multiple Sclerosis.
Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.
Increase in mRNA Level of Orexin1 and 2 Receptors Following Induction of Experimental Autoimmune Encephalomyelitis in Mice.
Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis
Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica.
Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis.
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
The Many Facets of Cell Injury: Angiogenesis to Autophagy.
Expression and activation by epstein barr virus of human endogenous retroviruses-w in blood cells and astrocytes: inference for multiple sclerosis.
Identification of the LDL Receptor-Related Protein-1 Interactome in Central Nervous System myelin suggests a role in the clearance of necrotic cell debris.
First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.
Gustatory Dysfunction in Multiple Sclerosis
Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis.
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with MS.
Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP
Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis.
Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord.
2nd Annual Congress on Neurology and Epidemiology
Depakote: No Prescription Cheap Low
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS)
Benefit of Endermology on Indurations and Panniculitis/Lipoatrophy During Relapsing-Remitting Multiple Sclerosis Long-Term Treatment with Glatiramer Acetate.
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)

Pages